UFT, a compound containing uracil and tegafur (a prodrug of 5-fluorouracil) in a 4:1 molar ratio, has been used in Japan for the treatment of and as adjuvant chemotherapy for bladder cancer. In phase II studies, 300 to 600
Yoshinobu Kubota, MD, PhD
Advertisement
Articles by Yoshinobu Kubota, MD, PhD
Advertisement
Latest Updated Articles
- UFT in Bladder Cancer
July 1st 1999
Advertisement
Advertisement
Trending on CancerNetwork
1
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
2
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
3
Ivonescimab Combo Yields Encouraging Activity in Previously Treated SCLC
4
BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma
5